Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
70.00
-0.82 (-1.16%)
Dec 12, 2025, 3:05 PM EST - Market open
Arrowhead Pharmaceuticals Revenue
In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth. Arrowhead Pharmaceuticals had revenue of $256.47M in the quarter ending September 30, 2025.
Revenue (ttm)
$829.45M
Revenue Growth
+23,258.15%
P/S Ratio
11.42
Revenue / Employee
$1,166,594
Employees
711
Market Cap
9.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | -2.50M | -65.69% |
| Sep 30, 2007 | 3.80M | 3.20M | 537.91% |
| Sep 30, 2006 | 595.46K | 4.78K | 0.81% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARWR News
- 4 days ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences - Business Wire
- 14 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript - Seeking Alpha
- 15 days ago - Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today - The Motley Fool
- 16 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results - Business Wire
- 18 days ago - Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire